Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 301–400 of 895
Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas
Shaker, N., Chen, W., Sinclair, W., Parwani, A. V., & Li, Z. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100038 · Cited by 42
Biomarker Expression in Pelvic High-grade Serous Carcinoma: Comparison of Ovarian and Omental Sites
Köbel, M., Turbin, D. A., Kalloger, S. E., Gao, D., Huntsman, D. D., & Gilks, C. B. (2011) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31820d20ba · Cited by 42
Self-citationTalhouk, A., Kommoss, S., Mackenzie, R., Cheung, M., Leung, S. C. Y., Chiu, D. S., Kalloger, S. E., Huntsman, D. D., Chen, S., Intermaggio, M. P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153844 · Cited by 42
“Similarly, OC samples were adjusted using the OVO data (OVO_ref), five samples from each carcinoma histotype[31] chosen at random (any5_ref), and the OVCL data (OVCL_ref; averaging over all OC cell lines).”
BackgroundMethodSelf-citationTwo new biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma
Hellström, I., & Hellström, K. E. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.559459 · Cited by 42
Protease inhibitor SERPINA1 expression in epithelial ovarian cancer
Normandin, K., Péant, B., Page, C. L., de Ladurantaye, M., Ouellet, V., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9303-6 · Cited by 42
“Moreover, results obtained with serous tissues cannot necessarily be applied to other subtypes since ovarian cancer subtypes have distinct biomarker expression profiles and are considered as different diseases [47].”
Redjimi, N., Gaudin, F., Touboul, C., Émilie, D., Pallardy, M. J., Biola‐Vidamment, A., Fernandez, H., Prevot, S., Balabanian, K., & Machelon, V. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-83 · Cited by 42
“Each subtype is characterized by specific genetic risk factors, molecular features, and mRNA expression profiles [32-34], suggesting that ovarian carcinoma is a heterogeneous disease [35].”
Asadi-Aghbolaghi, M., Farahani, H., Zhang, A. W., Akbari, A., Kim, S., Chow, A., Dane, S., Huntsman, D. D., Gilks, C. B., Ramus, S. J., et al. (2024) · medRxiv · doi:10.1101/2024.04.19.24306099 · Cited by 42
“However, histological classification of ovarian carcinomas by pathologists still suffers from suboptimal interobserver and intraobserver reproducibility outside of gynecologic pathology subspecialty practice and tertiary academic centers [3, 5–8].”
BackgroundSelf-citationSuzuki, H., Nagase, S., Saito, C., Takatsuka, A., Nagata, M., Honda, K., Kaneda, Y., Nishiya, Y., Honda, T., Ishizaka, T., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0287 · Cited by 41
“7), renal cell carcinoma (RCC; refs.”
Post, M. D. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.113 · Cited by 41
Li, H., Gong, J., Li, R. M., Xiao, Z. B., Qiang, J., Peng, W. J., & Gu, Y. J. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.20.23195 · Cited by 41
Nelson, B. H. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.004 · Cited by 41
How can molecular abnormalities influence our clinical approach
Wei, W., Giulia, F. M., Luffer, S., Kumar, R., Wu, B., Tavallai, M., Bekele, R., & Birrer, M. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx447 · Cited by 40
Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
Ballestrero, A., Bedognetti, D., Ferraioli, D., Franceschelli, P., Labidi‐Galy, S. I., Leo, E., Murai, J., Pommier, Y. G., Tsantoulis, P. K., Vellone, V. G., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1296-3 · Cited by 40
“Presented by Valerio Gaetano Vellone Epithelial carcinoma of the ovary has always been clinically considered as one disease, but there is now a much greater realization that the various subtypes have a different natural behavior and prognosis [20].”
BackgroundUse of a Single-Chain Antibody Library for Ovarian Cancer Biomarker Discovery
Ramirez, A. B., Loch, C. M., Zhang, Y., Liu, Y., Wang, X., Wayner, E. A., Sargent, J. E., Sibani, S., Hainsworth, E., Mendoza, E. A., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900496-mcp200 · Cited by 40
Riesco‐Eizaguirre, G., Leoni, S. G., Mendiola, M., Estevez-Cebrero, M. A., Gallego, M. I., Redondo, A., Hardisson, D., Santisteban, P., & la Vieja, A. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4249 · Cited by 40
“ian tumors as previously described (37).”
Keita, M., Bessette, P., Pelmus, M., Ainmelk, Y., & Aris, A. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-3 · Cited by 40
New therapies for clear cell ovarian carcinoma
Stewart, J., Cunningham, N., & Banerjee, S. N. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003704 · Cited by 39
Inhibitors of Matriptase‐2 Based on the Trypsin Inhibitor SFTI‐1
Gitlin‐Domagalska, A., Dębowski, D., Ptaszyńska, N., Łęgowska, A., Stirnberg, M., Gütschow, M., & Rolka, K. (2015) · ChemBioChem · doi:10.1002/cbic.201500200 · Cited by 39
Bourgeois, D. L., Kabarowski, K. A., Porubsky, V. L., & Kreeger, P. K. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0263-4 · Cited by 39
“High-grade serous ovarian cancer (HGSOC), a subtype characterized by a mutation in TP53, a low rate of other mutations, and extensive DNA copy number changes, is the most aggressive and most common subtype of ovarian cancer, accounting for two-thirds of deaths [2, 3].”
BackgroundSIRT1 in Secretory Organ Cancer
Frazzi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00569 · Cited by 39
Leandersson, P., Åkesson, A., Hedenfalk, I. A., Malander, S., & Borgfeldt, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240418 · Cited by 39
“Adding to the difficulties in identifying a biomarker panel with high sensitivity and specificity for ovarian cancer is the heterogeneity of the disease, with different morphological subtypes expressing different patterns of biomarkers [53,54].”
BackgroundMutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma
Zannoni, G. F., Improta, G., Chiarello, G., Pettinato, A., Petrillo, M., Scollo, P., Scambia, G., & Fraggetta, F. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1599-1 · Cited by 39
Modelling genetic and clinical heterogeneity in epithelial ovarian cancers
Lawrenson, K., Sproul, D., Grün, B., Notaridou, M., Benjamin, E. O., Jacobs, I. J., Dafou, D., Sims, A. H., & Gayther, S. A. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr140 · Cited by 39
Fridley, B. L., Dai, J., Raghavan, R., Li, Q., Winham, S. J., Hou, X., Weroha, S. J., Wang, C., Kalli, K. R., Cunningham, J. M., et al. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0728 · Cited by 39
Falkenthal, T. E. H., Nymoen, D. A., Emilsen, E., Kærn, J., Trope, C. G., Flørenes, V. A., & Davidson, B. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.029 · Cited by 38
Lee, S., Piskorz, A., Page, C. L., Mes‐Masson, A., Provencher, D. M., Huntsman, D. D., Chen, W., Swanson, P. E., Gilks, C. B., & Köbel, M. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000251 · Cited by 38
Self-citationSmith, G. C., Ng, M. T. H., Shepherd, L., Herrington, C. S., Gourley, C., Ferguson, M., & Wolf, C. R. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.410 · Cited by 38
“Ovarian cancer (ICD-10 C56) describes several related diseases with different cellular origins and molecular characteristics (Kobel et al, 2008).”
BackgroundCopy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?
Hunter, S. M., Anglesio, M. S., Sharma, R. N., Gilks, C. B., Melnyk, N., Chiew, Y.-E., DeFazio, A., Longacre, T. A., Huntsman, D. D., Gorringe, K. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2080 · Cited by 38
Self-citationSkírnisdóttir, I., & Seidal, T. (2013) · PubMed · Cited by 38
Cytokines and Prognostic Factors in Epithelial Ovarian Cancer
Jammal, M. P., Martins-Filho, A., Silveira, T. P., Murta, E. F. C., & Nomelini, R. S. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s38333 · Cited by 38
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4 · Cited by 38
Self-citationImmunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes
Ornella, M. S. C., Badrinath, N., Kim, K.-A., Kim, J. H., Cho, E., Hwang, T.-H., & Kim, J.-J. (2023) · Cancers · doi:10.3390/cancers15082383 · Cited by 37
“The monoclonal antibody called MOC31PE is derived from the Pseudomonas exotoxin A (PE) and targets the epithelial cell adhesion molecule (EpCAM), a transmembrane glycoprotein that is significantly overexpressed in cancerous tissue, including HGSOC, and is expressed at small levels in normal tissue [59,60].”
BackgroundImpact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis
Gannon, P. O., Medelci, S., Page, C. L., Beaulieu, M., Provencher, D. M., Mes‐Masson, A., & Santos, M. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25577 · Cited by 37
“This is important because ovarian cancer subtypes (serous, endometrioid, mucinous and clear cell) are increasingly being considered different diseases, with marked higher mortality being consistently observed in the high-grade serous subtype.(28)”
BackgroundSehouli, J., Braicu, E. I., Richter, R., Denkert, C., Jank, P., Jurmeister, P. S., Kunze, C. A., Budczies, J., Darb-Esfahani, S., Schmitt, W., et al. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.10.020 · Cited by 37
Wang, Y., Wang, Y., Li, J., Zeng, Y., Yuan, B., Zhang, T., Cragun, J. M., Kong, B., & Zheng, W. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-60 · Cited by 37
“This marker, initially identified in normal cells originating in Müllerian ducts, is also present in ovarian tumors and is characteristic for the epithelial phenotypes (serous, clear cell, and endometrioid) [5,21-23].”
BackgroundDarb‐Esfahani, S., Wirtz, R. M., Sinn, B. V., Budczies, J., Noske, A., Weichert, W., Faggad, A., Scharff, S., Sehouli, J., Oskay-Özcelik, G., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0338 · Cited by 37
“In the light of previous studies that showed a differential biomarker expression in different histological types of ovarian carcinoma (Köbel et al. 2008), we further investigated the largest histological subgroup of serous and undifferentiated carcinomas.”
BackgroundXiao, Q., Yang, H., Wentzensen, N., Hollenbeck, A. R., & Matthews, C. E. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0154 · Cited by 36
“subtype may have a different set of risk factors (26, 32, 33).”
Garg, G., Yılmaz, A., Kumar, P., Türkoğlu, O., Mutch, D. G., Powell, M. A., Rosen, B. P., Bahado-Singh, R. O., & Graham, S. F. (2018) · Metabolomics · doi:10.1007/s11306-018-1448-3 · Cited by 36
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
Khella, C. A., Mehta, G. A., Mehta, R. N., & Gatza, M. L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020149 · Cited by 38
Bartolomé, R. A., Robles, J., Martín‐Regalado, Á., Pintado‐Berninches, L., Burdiel, M., Jaén, M., Aizpurúa, C., Imbaud, J. I., & Casal, J. I. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12947 · Cited by 36
Matsuno, R. K., Sherman, M. E., Visvanathan, K., Goodman, M. T., Hernandez, B. Y., Lynch, C. F., Ioffe, O. B., Horio, D. T., Platz, C. E., Altekruse, S. F., et al. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0157-5 · Cited by 37
Liu, Z., Yamanouchi, K., Ohtao, T., Matsumura, S., Seino, M., Shridhar, V., Takahashi, T., Takahashi, K., & Kurachi, H. (2014) · PubMed · Cited by 36
Stanley, B., Hollis, R. L., Nunes, H., Towler, J. D., Yan, X., Rye, T., Dawson, C., Mackean, M., Nussey, F., Churchman, M., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.030 · Cited by 36
“There is clear evidence that each EOC subtype is a discrete 231 disease with unique molecular profiles, treatment responses and patient outcomes [19].”
BackgroundCorrection: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C. M., Prentice, L., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., et al. (2013) · PLoS ONE · doi:10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a · Cited by 36
“As noted previously high expression is most prevalent in MUC, followed by ENOCa and LGSC [2,4].”
BackgroundMethodSelf-citationYe, S., Yang, J., You, Y., Cao, D., Huang, H., Wu, M. P., Chen, J., Lang, J., & Shen, K. (2016) · Medicine · doi:10.1097/md.0000000000003003 · Cited by 35
Angioli, R., Plotti, F., Capriglione, S., Scaletta, G., Dugo, N., Aloisi, A., Piccolo, C. L., Vescovo, R. D., Terranova, C., & Zobel, B. B. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4181-z · Cited by 35
Okła, K., Surówka, J., Frąszczak, K., Czerwonka, A., Kaławaj, K., Wawruszak, A., Kotarski, J., & Wertel, I. (2018) · Tumor Biology · doi:10.1177/1010428318804937 · Cited by 35
Beddows, I., Fan, H., Heinze, K., Johnson, B. K., Leonova, A., Senz, J., Djirackor, S., Cho, K. R., Pearce, C. L., Huntsman, D. D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1362 · Cited by 36
Self-citationThe Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis
Gao, L., Cheng, H., Dong, L., Ye, X., Liu, Y.-T., Chang, X.-H., Cheng, Y., Chen, J., Q, R., & Cui, H. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900507 · Cited by 35
Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012
Epidemiology Working Group Steering Committee, O. C. A. C. M. O. T. E. S., Doherty, J. A., Jensen, A., Kelemen, L. E., Pearce, C. L., Poole, E., Schildkraut, J. M., Terry, K. L., Tworoger, S. S., Webb, P. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx114 · Cited by 35
Making new biomarkers a reality: the case of serum human epididymis protein 4
Ferraro, S., & Panteghini, M. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1111 · Cited by 35
Kuhn, E., Meeker, A. K., Visvanathan, K., Gross, A. L., Wang, T., Kurman, R. J., & Shih, I. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.67 · Cited by 35
Different gene expression profiles in metastasizing midgut carcinoid tumors
Edfeldt, K., Björklund, P., Åkerström, G., Westin, G., Hellman, P., & Stalberg, P. L. H. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0256 · Cited by 34
“2002) and is implicated as a prognostic marker in ovarian carcinomas (Kobel et al. 2008).”
BackgroundHu, A., Li, H., Zhang, L., Ren, C., Wang, Y., Liu, Y., & Liu, C. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202951 · Cited by 34
Zhao, Y., Zong, Z., & Xu, H. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.015 · Cited by 34
Haslene‐Hox, H., Oveland, E., Woie, K., Salvesen, H. B., Wiig, H., & Tenstad, O. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.05.011 · Cited by 34
Quinn, M. C. J., Wojnarowicz, P. M., Pickett, A., Provencher, D. M., Mes‐Masson, A., Davis, E. C., & Tonin, P. N. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1797 · Cited by 34
The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms
Liu, H., Shi, J., & Lin, F. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000332 · Cited by 34
“cPTC (31) 4 4 12 10 30 (97) FVPTC (17) 2 3 6 2 13 (76) FA (51) 0* 0 0 0 0 FC (37) 0w 0w 0 0 0”
Specialized Pathology Review in Patients With Ovarian Cancer
Kommoss, S., Pfisterer, J., Reuß, A., Diebold, J., Hauptmann, S., Schmidt, C., du Bois, A., Schmidt, D., & Kommoss, F. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182a01813 · Cited by 34
“Considerable evidence already shows that the histological types of ovarian carcinoma are distinct diseaseswith specificmolecular features, treatment responses, and patient demographics.(22,25) This evidence is continuing to grow as more type-specific studies and trials are undertaken.”
BackgroundCasey, L., Köbel, M., Ganesan, R., Tam, S., Prasad, R., Böhm, S., Lockley, M., Jeyarajah, A., Brockbank, E. C., Faruqi, A. Z., et al. (2017) · Histopathology · doi:10.1111/his.13272 · Cited by 34
“Although these showed conflicting results when they included ovarian malignancies of all histotypes,(18) studies that have clearly separated different histotypes or included only HGSC have also found that WT1 expression has prognostic significance.(19,20) As diminution of WT1 expression was associated with unfavourabl…”
ResultSelf-citationValue of PAX2 Immunostaining in Tumor Diagnosis: A Review and Update
Ordóñez, N. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318271a382 · Cited by 34
“Serous carcinoma, metastatic 53 23 (43) 118 107 (91) Clear cell carcinoma, metastatic 2 1 (50) 7 7 (100) Endometrium Serous carcinoma 11 6 (55) 24 24 (100)”
Immunohistology of the Female Genital Tract
Rabban, J. T., Soslow, R. A., & Zaloudek, C. Z. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5766-6.00022-4 · Cited by 34
Mungenast, F., Aust, S., Vergote, I., Vanderstichele, A., Sehouli, J., Braicu, E., Mahner, S., Castillo-Tong, D. C., Zeillinger, R., & Thalhammer, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.5969 · Cited by 33
“As it is recommended to perform survival analyses for different ovarian cancer subtypes separately (33), a homogenous group of patients with a long observation period were used for survival analyses.”
Biomarkers in high grade serous ovarian cancer
Bates, M., Mohamed, B. M., Lewis, F., O’Toole, S. A., & O’Leary, J. J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189224 · Cited by 33
Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis
Pawar, N. R., Buzza, M. S., Duru, N., Strong, A. A., & Antalis, T. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202209114 · Cited by 34
“…of matriptase to HAI-1 may explain why some studies find that increased matriptase expression correlates with advanced clinical stages of OvCa (Jin et al., 2006; Tanimoto et al., 2005), while others report no significant changes in matriptase expression across OvCa stages (K¨obel et al., 2008).”
Expression of classical NF‐κB pathway effectors in human ovarian carcinoma
Darb‐Esfahani, S., Sinn, B. V., Weichert, W., Budczies, J., Lehmann, A., Noske, A., Buckendahl, A., Müller, B. M., Sehouli, J., Koensgen, D., et al. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03544.x · Cited by 33
“HeLa cells were used as a control.(20) As shown in Figure 3A, p65 DNA-binding activity was strongly inducible by 1 h of IL-1b treatment in OVCAR-3 cells and reached similar levels as in tumour necrosis factor-alpha (TNF-a)-induced HeLa cells.”
MethodExperimental validation of 5 in-silico predicted glioma biomarkers
Towner, R. A., Jensen, R. L., Vaillant, B. D., Colman, H., Saunders, D., Giles, C. B., & Wren, J. D. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not124 · Cited by 33
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells
Hoskins, E. R., Rodriguez‐Canales, J., Hewitt, S. M., ElMasri, W. M., Han, J. J., Han, S., Davidson, B., & Kohn, E. C. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.04.052 · Cited by 32
Kelemen, L. E., Rambau, P., Koziak, J. M., Steed, H. L., & Köbel, M. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0855-5 · Cited by 32
Self-citationZanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 32
Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery
Solidoro, R., Centonze, A., Miciaccia, M., Baldelli, O. M., Armenise, D., Ferorelli, S., Perrone, M. G., & Scilimati, A. (2024) · Medicinal Research Reviews · doi:10.1002/med.22027 · Cited by 32
Davis, S. J., Sheppard, K. E., Anglesio, M. S., George, J., Traficante, N., Fereday, S., Intermaggio, M. P., Menon, U., Gentry‐Maharaj, A., Lubiński, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0039 · Cited by 32
“Ovarian cancer is defined histologically into the serous (low and high grade), clear cell, endometrioid and mucinous tumour subtypes (3).”
BackgroundSelf-citationCathepsins B, L and cystatin C in cyst fluid of ovarian tumors
Kolwijck, E., Massuger, L. F. A. G., Thomas, C. M. G., Span, P. N., Krašovec, M., Kos, J., & Sweep, F. C. G. J. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0716-z · Cited by 32
“This Wnding contributes to the theory that malignant serous and mucinous ovarian tumors are diVerent diseases, with subtype-speciWc biomarker proWles (Heinzelmann-Schwarz et al. 2006; Kobel et al. 2008; Cloven et al. 2004).”
BackgroundVermeij, R., de Bock, G. H., Leffers, N., ten Hoor, K. A., Schulze, U., Hollema, H., van der Burg, S. H., van der Zee, A. G. J., Daemen, T., & Nijman, H. W. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821e012f · Cited by 32
Hanaoka, T., Hasegawa, K., Kato, T., Sato, S., Kurosaki, A., Miyara, A., Nagao, S., Seki, H., Yasuda, M., & Fujiwara, K. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0255-2 · Cited by 32
Origins based clinical and molecular complexities of epithelial ovarian cancer
Muinao, T., Pal, M., & Boruah, H. P. D. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.06.036 · Cited by 32
Human Epididymis Protein 4 in Cancer Diagnostics
Speeckaert, M. M., Speeckaert, R., & Delanghe, J. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-405211-6.00001-2 · Cited by 32
Lurie, G., Wilkens, L. R., Thompson, P. J., Matsuno, R. K., Carney, M. E., & Goodman, M. T. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.028 · Cited by 32
“It has long been recognized that ovarian cancer histological subtypes are associated with different natural histories [9].”
BackgroundRole of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
Ledermann, J. A., Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I. A., Oza, A. M., Scambia, G., Rustin, G. J. S., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821b2669 · Cited by 31
“16,17 They differ substantially from the genetically unstable high-grade serous tumors and immunohistochemically have very different expression patterns.(18) It is important in future trials that the rarer histological subtypes are studied individually, or as groups that contain similar molecular features appropriate…”
BackgroundD’Alessandris, N., Travaglino, A., Santoro, A., Arciuolo, D., Scaglione, G., Raffone, A., Inzani, F. S., & Zannoni, G. F. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.011 · Cited by 31
A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
Němejcová, K., Šafanda, A., Bártů, M., Michálková, R., Drozenová, J., Fabián, P., Hausnerová, J., Laco, J., Matěj, R., Méhes, G., et al. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01317-9 · Cited by 31
“endometrioid, and clear cell carcinomas [25].”
Backgroundp53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Köbel, M., Kang, E., Weir, A. L., Rambau, P., Lee, C., Nelson, G. S., Ghatage, P., Meagher, N. S., Riggan, M. J., Alsop, J., et al. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.311 · Cited by 31
“Analyses were grouped for a binary comparison of cases with abnormal versus normal p53 IHC separately for EC and CCC [27].”
MethodSelf-citationBrowne, A. L., Sriraksa, R., Güney, T. G., Rama, N., Noorden, S. V., Curry, E. W., Gabra, H., Stronach, E. A., & El-Bahrawy, M. A. (2013) · Cytokine · doi:10.1016/j.cyto.2013.05.006 · Cited by 31
“The correlation between histological subtype of carcinoma and the expression of biomarkers such as IL-8 and its receptors at the stage of diagnosis may determine the treatment type and overall prognosis [26].”
BackgroundHMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Falkenthal, T. E. H., Holth, A., Kærn, J., Flørenes, V. A., Trope, C. G., & Davidson, B. (2012) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-012-1228-9 · Cited by 31
“OC carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are recognized as different diseases with variable expression of biomarkers [29], and we therefore included only patients with serous histology in our cohort.”
BackgroundCurrent Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer
Zhang, K., Zhou, S., Wang, L., Wang, J., Zou, Q., Zhao, W., Fu, Q., & Fang, X. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071163 · Cited by 31
“Trop2 is highly expressed in epithelial related cancers, and its protein level often correlates with poor prognosis [68–73].”
BackgroundEmerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 31
Perez-Juarez, C. E., Arechavaleta-Velasco, F., Zeferino-Toquero, M., Álvarez‐Arellano, L., Estrada-Moscoso, I., & Díaz-Cueto, L. (2019) · Medical Oncology · doi:10.1007/s12032-019-1326-5 · Cited by 30
“endometrioid adenocarcinoma, mucinous adenocarcinoma, and clear cell carcinoma [3, 4].”
Rödel, F., Zhou, S., Győrffy, B., Raab, M., Sanhaji, M., Mandal, R., Martin, D., Becker, S., & Strebhardt, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.558932 · Cited by 30
Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium
Lawrenson, K., Pakzamir, E., Liu, B., Lee, J. M., Delgado, M. K., Duncan, K., Gayther, S. A., Liu, S., Roman, L. D., & Mhawech-Fauceglia, P. Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130909 · Cited by 30
“However it is also plausible that novel MT-EC specific biomarkers will exist; and it is notable that the top biomarker identified as differentially expressed between pure and mixed cases was PAX8, a candidate gene included because of the common expression of this biomarker in high-grade serous and clear cell ovarian c…”
BackgroundTownsend, K. N., Spowart, J. E., Huwait, H., Eshragh, S., West, N. R., Elrick, M. A., Kalloger, S. E., Anglesio, M., Watson, P. H., Huntsman, D. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082406 · Cited by 29
“The retrospective patient cohort used for this study has been described previously [45].”
MethodSelf-citationCXCL12 expression by healthy and malignant ovarian epithelial cells
Machelon, V., Gaudin, F., Camilleri‐Broët, S., Nasreddine, S., Bouchet‐Delbos, L., Pujade-Lauraine, É., Alexandre, J., Gladieff, L., Arenzana‐Seisdedos, F., Émilie, D., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-97 · Cited by 29
“This aspect has recently been addressed with the identification of several biomarkers for the identification of histologic subtypes and the more accurate prediction of patient outcome [4-9].”
BackgroundKong, X., Chang, X., Cheng, H., Ma, R., Ye, X., & Cui, H. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000078 · Cited by 29
“Over the past decade, it has been used widely for the early screening and differential diagnosis of ovarian carcinoma and for monitoring disease recurrence(10) and progression.(11) Little is known about the influence of HE4 on ovarian cancer, and the signaling pathways through which HE4 exerts its effects have not bee…”
BackgroundYang, Z., LUO, Z., Zhao, B., Zhang, W., Zhang, J., Zhuang, L., & Li, L. (2013) · Oncology Letters · doi:10.3892/ol.2013.1339 · Cited by 29
“The present study also was consistent with Köbel et al 's results (9).”
Seidman, J. D., VANG, R. S., Ronnett, B. M., Yemelyanova, A. V., & Cosin, J. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.018 · Cited by 29
High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population
Ingerslev, K., Høgdall, E. V. S., Skovrider‐Ruminski, W., Schnack, T. H., Karlsen, M. A., Nedergaard, L., Høgdall, C. K., & Blaakær, J. (2016) · Infectious Agents and Cancer · doi:10.1186/s13027-016-0087-4 · Cited by 29
“pathogenetic pathways [19, 20], and therefore, it may be assumed that the etiologic factors differ among subtypes.”
BackgroundCao, H., You, D., Zhu, L., Ye, H., Hou, M., & Xi, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1457436 · Cited by 29
“33 ) N A N A 6 Li W 20 17 Ch in a 45 Ch in es e I– IV Ti ss ue IH C 77 .7 8 H -s co re > 2 N A N A N A N A N A 5 Li X 20 17 Ch in a 36 Ch in es e I– IV Se ru m EL IS A N A N A N A N A N A N A N A 5 Zh u P 20 17 Ch in a 41 Ch in es e I– IV Se ru m EL IS A N A N A N A N A N A N A N A 5 N A: no t av ai la bl e; IH C: im…”
BackgroundXie, T., Dickson, K.-A., Yee, C., Ma, Y., Ford, C. E., Bowden, N. A., & Marsh, D. J. (2022) · Cancers · doi:10.3390/cancers14194621 · Cited by 28
Gorbokon, N., Baltruschat, S., Lennartz, M., Luebke, A. M., Höflmayer, D., Kluth, M., Hube‐Magg, C., Hinsch, A., Fraune, C., Lebok, P., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03872-y · Cited by 28
“…carcinoma [22, 38], from 0 to 83% in cervical adenocarcinoma [43, 46], from 0 to 75% in medullary thyroid cancer [22, 29], from 31 to 100% in papillary thyroid carcinoma [20, 54], from 42 to 95% in renal oncocytoma [46, 55], and from 38 to 100% in endometrioid adenocarcinoma of the ovary [12, 18].”
Li, H. M., Zhang, R., Gu, W. Y., Zhao, S., Lü, N., Zhang, G. F., Peng, W. J., & Qiang, J. (2019) · Clinical Radiology · doi:10.1016/j.crad.2019.07.019 · Cited by 28
Sheta, R., Bachvarova, M., Plante, M., Renaud, M., Sebastianelli, A., Gregoire, J., Navarro, J. M., Bringas, R., Masson, J., & Bachvarov, D. R. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02613-4 · Cited by 29
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.